Ceftazidime最近在美国上市,商品名:Fortaz(Glaxo公司),供注射用于治疗敏感菌株引起的各种感染。本品具广谱抗菌活性包括革蓝氏阳性球菌[但肠球菌和耐甲氧西林(Methicillin)的金黄色葡萄球菌除外]、肠系革蓝氏阴性杆菌、绝大多数绿脓杆菌、洋葱假单孢菌、不动杆菌和其它非发酵菌及许多厌氧菌,但不包括梭状芽孢杆菌(C. difficile)和绝大多数脆弱拟杆菌。绝大多数淋球菌(包括产生青霉素酶的菌株)、脑膜炎球菌和流感杆菌(包括耐氨苄青霉素和/或氯霉素的菌株)均对本品高度敏感。李氏单核增多菌对本品耐药。 Ceftazidime在体外对肺炎球菌和A、B Ceftazidime is recently marketed in the United States under the trade name Fortaz (Glaxo) for injection for the treatment of various infections caused by susceptible strains. This product has a broad-spectrum antibacterial activity including gram-positive cocci [except enterococci and methicillin-resistant Staphylococcus aureus), gram-negative Gram-negative bacilli, most of Pseudomonas aeruginosa, onion leave Monascus, Acinetobacter and other non-fermentable bacteria and many anaerobic bacteria, but not C. difficile and most B. fragilis. Neisseria gonorrhoeae (including penicillinase-producing strains), meningococci and influenza (including ampicillin and / or chloramphenicol resistant strains) are highly sensitive to this product. Listeria monocytogenes resistant to the drug. Ceftazidime in vitro against pneumococci and A, B